News | May 10, 2007

New Data Show Diagnostic Test Reduces Mortality, Costs Associated with BSI

May 11, 2007 - AdvanDx Inc. announced a group of infectious disease specialists, headed by Shmuel Shoham M.D. at the Washington Hospital Center, revealed new clinical data that demonstrated how AdvanDx's PNA FISH diagnostic test reduced mortality and hospital costs associated with staphylococcal bloodstream infections (BSI).

PNA FISH is a rapid, molecular-based test that identifies bacteria and yeast species directly from positive blood cultures. Results are available within hours instead of days, enabling labs to quickly report results to physicians and pharmacists to ensure optimal therapy and reduced death rates for patients afflicted with staphylococcal bloodstream infections. Dr. Shoham presented the data at the 2007 Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. The study occurred at the Washington Hospital Center, which is the largest hospital in the nation's capital and among the 25 largest hospitals in the U.S.

Every year, 350,000 patients acquire bloodstream infections in the U.S., resulting in more than 90,000 deaths and significant costs to the healthcare system. Rapid identification of the causative pathogen ensures early and effective therapy in order to improve patient outcomes. During the study, 202 patients whose blood culture tested positive for Gram-positive cocci (indicating a staphylococcal bloodstream infection) were alternately assigned to a control, or intervention, group. In the intervention group, PNA FISH results and general organism information were relayed to the treating clinician via a call from a hospital liaison, whereas control group patients did not receive a call with PNA FISH results. According to the study, reporting of PNA FISH results led to:

• An 80 percent reduction in intensive care unit (ICU) related mortality due to S. aureus BSIs;
• Median hospital cost savings of $19,441 per patient;
• A 61 percent reduction in patients receiving antibiotics for coagulase-negative staphylococci (CNS), which is often a blood culture contaminant that leads to unnecessary antibiotic therapy even though the patient does not have a true bloodstream infection.

For more information visit www.AdvanDx.com.

Related Content

Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
Videos | Advanced Visualization | March 05, 2019
This is an example of a new endoscopic virtual peritoneal inflation tool on the patient's computed tomography (CT) im
Videos | Advanced Visualization | March 05, 2019
This is an example of a new endoscopic 3-D imaging simulator created from a patient's computed tomography (CT) scan u
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
American Society for Gastrointestinal Endoscopy and Touch Surgery Pilot Video-Based Endoscopic Simulations
News | Endoscopes | June 11, 2018
During the 2018 Digestive Disease Week (DDW) conference June 2-5 in Washington, D.C., the American Society for...
Olympus and Hitachi Healthcare Americas Introduce Arietta 850
News | Ultrasound Imaging | June 04, 2018
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedu
Body Vision Medical Receives FDA Clearance for LungVision Tool
Technology | Lung Cancer | May 09, 2018
Body Vision Medical received clearance from the U.S. Food and Drug Administration (FDA) to market their LungVision Tool...
El Camino Hospital Performs First U.S. Robotic Lung Cancer Bronchoscopy
News | Oncology Diagnostics | April 25, 2018
The interventional pulmonology team at the Taft Center for Clinical Research at El Camino Hospital in Mountain View,...
News | Endoscopes | April 02, 2018
Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D)...